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Background: Vancomycin is the first-line antibiotic for methicillin-resistant Staphylococcus aureus and coagulase-
negative strains. The risk of vancomycin-induced acute kidney injury increases with plasma vancomycin levels.
Vancomycin-induced acute kidney injury is histologically characterized by acute interstitial nephritis and/or acute
tubular necrosis. However, only 12 biopsy-proven cases of vancomycin-induced acute kidney injury have been
reported so far, as renal biopsy is rarely performed for such cases. Current recommendations for the prevention
or treatment of vancomycin-induced acute kidney injury are drug monitoring of plasma vancomycin levels using
trough level and drug withdrawal. Oral prednisone and high-flux haemodialysis have led to the successful recovery of
renal function in some biopsy-proven cases.
Case presentation: We present the case of a 41-year-old man with type 1 diabetes mellitus, who developed
vancomycin-induced acute kidney injury during treatment for Fournier gangrene. His serum creatinine level
increased to 1020.1 μmol/L from a baseline of 79.6 μmol/L, and his plasma trough level of vancomycin peaked at 80.
48 μg/mL. Vancomycin discontinuation and frequent haemodialysis with high-flux membrane were immediately
performed following diagnosis. Renal biopsy showed acute tubular necrosis and focal acute interstitial nephritis,
mainly in the medullary rays (medullary ray injury). There was no sign of glomerulonephritis, but mild diabetic
changes were detected. He was discharged without continuing haemodialysis (serum creatinine level, 145.0 μmol/L)
49 days after initial vancomycin administration.
Conclusions: This case suggests that frequent haemodialysis and renal biopsy could be useful for the treatment and
assessment of vancomycin-induced acute kidney injury, particularly in high-risk cases or patients with other
renal disorders.
Keywords: Acute kidney injury, Acute interstitial nephritis, Acute tubular necrosis, High-flux haemodialysis, VancomycinBackground
Intravenous vancomycin (VCM) is the antibiotic of first
choice for methicillin-resistant Staphylococcus aureus
and S. epidermidis infections [1]. The increasing use of
higher VCM doses has led to a higher incidence of
VCM-induced acute kidney injury (AKI) [2], particularly
in patients with risk factors such as hospitalization in* Correspondence: anri-sawada@nms.ac.jp
1Department of Surgical Pathology, Tokyo Women’s Medical University, 8-1
Kawadacho, Shinjuku, Tokyo 162-8666, Japan
2Department of Medicine Kidney Center, Tokyo Women’s Medical University,
Tokyo, Japan
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zethe Intensive Care Unit, obesity, and pre-existing chronic
kidney disease, although most of the evidence was based
on observational studies [3]. The mechanism behind
VCM-induced AKI is still uncertain; however, animal
models and a few biopsy-proven cases have shown that
VCM could induce acute interstitial nephritis (AIN)
and/or acute tubular necrosis (ATN) [4]. A common
strategy for preventing and treating VCM-induced AKI
is monitoring plasma VCM levels and subsequent
VCM withdrawal as necessary [3]. Haemodialysis, par-
ticularly high-flux haemodialysis, may be useful in a
more effective removal of VCM in some cases [5–7].le is distributed under the terms of the Creative Commons Attribution 4.0
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cases of AIN [6, 8–11]. Here we present a biopsy-
proven case of VCM-induced AKI in a patient with
Fournier gangrene and type 1 diabetes mellitus (DM)
and review previous published cases.Case presentation
We present the case of a 41-year-old man who had been
diagnosed with type 1 DM in junior high school. He was
168 cm tall and weighed 90.0 kg (body mass index,
31.9 kg/m2). His baseline serum creatinine (sCr) level
was 79.6 μmol/L and his urinary protein level was 0.3 g/
gCr. His blood pressure was well controlled with an al-
dosterone receptor blocker. DM control was poor
(haemoglobin A1c 9.0–10.0%) under intensive conven-
tional insulin therapy. His diabetic retinopathy was
simple type. Pregabalin, duloxetine and mexiletine were
also used for diabetic neuropathy. His family history was
not significant except cerebral infarction in his grand-
mother. He initially visited a primary care unit because
of general fatigue and high fever and was given oral
levofloxacin. However, he later called an urgent care unit
because of swelling and pain in his genitals. He was
diagnosed with Fournier gangrene and admitted to
our hospital (Fig. 1, clinical course). Table 1 showed
urinary, blood and culture examination on admission.
Inflammatory markers were elevated (white blood cell
count 25,700/μL with left shift and C reactive protein
28.8 mg/L). Renal function was slightly abnormalFig. 1 Clinical course for the treatment of Fournier gangrene and vancomy
biaxis shows the serum creatinine level (sCr, red), urinary volume (yellow), and
dosages were 3.0 g/day, then increased to 4.5 g/day. VCM, vancomycin; HD, h
Sulbactam; LVFX, Levofloxacin; CLDM, Clindamycin(Blood urine nitrogen 22.0 mg/dL, sCr 91.1 μmol/L)
and proteinuria was detected. Blood culture was
negative. Escherichia coli and Enterococcus faecalis
were detected from wound culture. Free air was noted
in his genital area via computed tomography (CT)
scan (Fig. 2a). He underwent debridement and received
tazobactam/piperacillin (PIPC/TAZ) 4.5 g every 8 h and
intravenous VCM 1.5 g every 12 h. Because his trough
VCM level was still low (9.24 μg/mL, 15–20 μg/mL is for
complicated infections [12]) and sCr stable (83.1 μmol/L)
on day 3, intravenous VCM increased to 1.5 g every 8 h.
Thereafter, he developed pitting pedal edema, weight gain
(10 kg), reduced urine volume (100 mL/day), increased
sCr (416.4 μmol/L) and trough VCM level (80.48 μg/
mL) on day 6, which suggested VCM-induced AKI.
Urinary examination results, which included N-acetyl-
beta-D-glucosaminidase of 32.0 U/L, α1-microgloblin
of 25.7 mg/L, and β2-microgloblin of 1800 μg/L, were
also consistent with AKI. CT scan showed no signs of
hydronephrosis or renal atrophy (Fig. 2b). Gallium
scintigraphy showed significant accumulation in both
kidneys (Fig. 2c).
VCM and PIPC/TAZ were switched to ampicillin/sul-
bactam (ABPC/SBT), and frequent haemodialysis was
performed on days 6–17, a total of seven times over
12 days (seven 4-h sessions with a blood flow rate of
120–150 mL/min and dialysate flow rate of 500 mL/
min). Ethylene vinyl alcohol membrane was used on
days 6 and 7, whereas polysulfone membrane was used
on days 9, 11, 12, 14, and 17. His urine volume began tocin-induced acute kidney injury in a 41-year-old man. The vertical
plasma trough level of vancomycin (green). Intravenous vancomycin
aemodialysis, PIPC/TZA, Piperacillin/Tazobactam; ABPC/SBT, Ampicillin/
Table 1 Laboratory data on admission
Complete blood cell count
White blood cell (/μL) 25,700
Red blood cell (× 104/μL) 476
Haemoglobin (g/dL) 13.6
Haematocrit (%) 38.6
Platelets (× 104/μL) 20.7
Serum chemistries
Total protein (g/dL) 6.1
Albumin (g/dL) 2.9
Blood urine nitrogen (mg/dL) 22.0
Creatinine (μmol/L) 91.1




C reactive protein (mg/dL) 28.8






Red blood cell sediment 1–4/hpf
White blood cell sediment 5–9/hpf
Cultivation
Blood culture negative
Wound culture E. coli, E. faecallis
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A renal biopsy was performed on day 18 to rule out
other renal disorders and evaluate for diabetic nephropa-
thy. ABPC/SBT was switched to ciprofloxacin on day 13
because of a rash that developed mainly on his abdomen
and back, and clindamycin was added on days 16–22.
He was discharged on day 49 without haemodialysis andFig. 2 a Computed tomography image showing free air in the genital lesio
hydronephrosis or renal atrophy. c Gallium scintigraphy showing significanantibiotics (sCr, 145.0 μmol/L). Eight months later, his
sCr was decreased to 109.6 μmol/L.Renal biopsy
The specimen included 16 glomeruli with cortex (no
medulla). Subcapsular and medullary ray fibrosis was
found in 10% of the specimen on Masson staining
(Fig. 3a). Glomeruli showed no sclerotic or inflammatory
changes, but mild mesangial expansion without signifi-
cant depositions of immunoglobulin or complement in
immunofluorescence was found. Nodular lesions were
not detected (Fig. 3b). Focal but severe AIN (Fig. 3c)
and tubular epithelium injury with nuclear denudation
or tubular dilatation (ATN) (Fig. 3d) were detected.
Interstitial monocyte infiltration and tubulitis were
mainly distributed in the medullary ray lesions (Fig. 3e).
There were no obvious eosinophilic infiltrations or
granular lesions in the specimen. Mild intimal fibrosis
was found in some of the small interlobular arteries, and
mild hyalinosis was also noted in an arteriole. In
summary, the kidney biopsy showed that ATN and focal
AIN with mild diabetic nephropathy.Discussion
In general, an AKI episode is an independent risk factor
for end-stage renal disease and death, and patients with
pre-existing chronic kidney disease (CKD) are at higher
risk for long-term mortality and dialysis after hospital
discharge [13].
The first case series of VCM-induced AKI was
reported in 1958 [14]. The incidence of VCM-induced
nephrotoxicity was reported in approximately 5% of
patients [2]. VCM-induced AKI is initially diagnosed
when 50% sCr (or 44.2 μmol/l) elevation from baseline
is detected in at least two different time points after
administration of VCM treatment [15]. However, many
of recent studies are committed to the definition and
classification of AKI of RIFLE, AKIN and KDIGO
criteria [16–18].n (white arrow). b Computed tomography image showing no sign of
t accumulation in both kidneys (yellow arrows)
Fig. 3 Kidney biopsy slide specimen showing: a subcapsular and medullary ray fibrosis in 10% of the specimen, b mild mesangial expansion in
the glomeruli, c focal but severe lymphocyte infiltration and tubulitis, d tubular epithelium injury with nuclear denudation or tubular dilatation,
and e interstitial monocyte infiltration and tubulitis mainly distributed in the medullary ray lesion [a, Masson trichrome, × 2; b, c, Periodic acid–Schiff, ×
40 and × 20, respectively; d, Periodic acid–methenamine–silver, × 40; e, Tamm–Horsfall protein staining added on Periodic acid–Schiff, × 10]
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propriate range to prevent VCM-induced AKI. Plasma
VCM level could be measured with therapeutic drug
monitoring (TDM), such as VCM trough and area
under the curve (AUC). However, VCM trough and
AUC might be insufficient for prediction of VCM-
induced AKI in large population study [19]. Moreover,
available TDM guidelines still need optimizations to
establish a more reliable VCM-TDM strategy in
accordance with risk factors [20]. Previous studies
showed that minimal sCr elevation is associated with
prognosis of AKI [21], and intensive monitoring of
urine output could be useful for AKI diagnosis and
better outcomes [22]. More careful monitoring should
be used to detect AKI as soon as possible in VCM usage.
Although VCM nephrotoxicity was well known in
clinical settings, only 12 cases of biopsy-proven VCM-
induced AKI have been reported so far as renal biopsy
is rarely performed for such cases (Table 2) [4–11, 23–25].
Most of them showed AIN, and three cases showed
ATN. Renal biopsy in our case (peak sCr, 1020.1 μmol/L)
and one of the reported cases (peak sCr, 1034.3 μmol/L)
revealed ATN and AIN. Diabetic nephropathy [11],
IgA nephropathy [11], and lupus nephritis [25] were
found simultaneously.
Although the mechanism of kidney injury is still un-
known, VCM induced oxidative stress that promotesreactive oxygen species was thought to be the main
one [26]. Animal study showed that VCM induced
renal tubular injuries were ameliorated by the use of
antioxidants [26, 27]. An allergic reaction could be
responsible to VCM induced AIN [11]. A case of
recurrent AIN after secondary challenge of VCM also
implied such an immunologic reaction [28].
Meanwhile, it is difficult to define what is cause of
VCM-induced AKI in clinical cases; synergistic toxicity
of VCM and other antibiotics such as PIPC/TAZ, cefe-
pime, aminoglycoside should be considered in the
current case as shown in previous studies [29–31]. Other
multiple drug usages could affect VCM pharmaco-
kinetics. Furthermore, VCM-induced AKI is more likely
to occur in pre-existing renal disease [3].
In our case, nephrotoxicity of VCM could be enhanced
in combination with PIPC/TAZ, which can decrease
VCM clearance, and elevate plasma VCM level [29].
Renal biopsy was necessary in our case, because we need
to differentiate other renal diseases such as glome-
rulonephritis and diabetic nephropathy for proteinuria
on admission and continuous oliguria. The renal biopsy
showed ATN and localized AIN with mild diabetic
nephropathy, which suggested that the main cause of
AKI was considered to be VCM induced ATN and AIN.
AIN caused by ABPC/SBT should be considered, be-
cause this case showed rash. Although ABPC/SBT
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ABPC/SBT usage by itself [32, 33].
In previous cases of biopsy-proven VCM-induced AKI,
diffuse or focal ATN was related to relatively higher
levels of sCr [4, 7, 24, 25], and one case with severe
ATN needed to continue haemodialysis for at least
2 months after treatments [24]. Oral prednisone therapy
has been attempted in AIN cases [6, 8–11], but has not
been established for VCM-induced AKI. Oral prednisone
therapy was not attempted in our case because he had
poor controlled DM and frontier gangrene. Renal biopsy
result (localized AIN) was commit to our decision on no
steroid use in the retrospective view. However, if AIN
lesion is more expanded, oral prednisone should be
considered to treat not only for VCM-induced AKI but
for possible side effects of ABPC/SBT.
Haemodialysis, particularly high-flux haemodialysis,
might be useful in a more effective removal of VCM in
some cases [5–7]. In paediatric cases, reducing plasma
VCM levels by high-flux haemodialysis contributed to
the good renal prognosis [7, 34]. In our case, frequent
haemodialysis with high-flux filters was performedseven times over 12 days, and urine volume was
increased right after plasma vancomycin level was
decreased (Fig. 1).
VCM is composed of a large glycopeptide compound
(molecular weight, 1450 Da) [35] with a heterogeneous
protein-binding rate (24.3–64%) [36]. Although conven-
tional haemodialysis membranes such as cuprophan
cannot adequately remove VCM (removal rate, 6%) [37],
high-flux filters such as polysulphone, polynitrile, and
polymethylmethacrylate can remove VCM from patients
more effectively (35–46%) [37, 38]. However, rebounding
of plasma VCM 3–6 h after haemodialysis was also
reported [37], which suggests that frequent haemo-
dialysis could be more useful. In our case, removal
rates of plasma VCM were 10.3–20.3% using ethylene
vinyl alcohol membrane and 13.2–35.2% using poly-
sulfone membrane.
Conclusion
In summary, we present an adult patient with type 1
DM who developed VCM-induced AKI during treatment
for Fournier gangrene. Early diagnosis and treatment led
Sawada et al. BMC Nephrology  (2018) 19:72 Page 6 of 7to the successful recovery of his renal function. This
case suggests that more careful VCM-TDM and inten-
sive monitoring of sCr and urinary output to detect
AKI should be considered in VCM usage. For the
diagnosis, renal biopsy of VCM induced AKI is useful
to assessment prognostic and therapeutic option in
cases at a high risk or those with other renal disorders.
For the treatment, frequent haemodialysis could be
useful in high concentration plasma VCM.
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